[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease - PubMed (original) (raw)
doi: 10.1016/j.jalz.2012.11.008. Epub 2013 Feb 12.
Janna Arteaga, Gang Chen, Umesh Gangadharmath, Luis F Gomez, Dhanalakshmi Kasi, Chung Lam, Qianwa Liang, Changhui Liu, Vani P Mocharla, Fanrong Mu, Anjana Sinha, Helen Su, A Katrin Szardenings, Joseph C Walsh, Eric Wang, Chul Yu, Wei Zhang, Tieming Zhao, Hartmuth C Kolb
Affiliations
- PMID: 23411393
- DOI: 10.1016/j.jalz.2012.11.008
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Chun-Fang Xia et al. Alzheimers Dement. 2013 Nov.
Abstract
Objective: We wished to develop a highly selective positron emission tomography (PET) imaging agent targeting PHF-tau in human Alzheimer's disease (AD) brains.
Methods: To screen potential tau binders, human AD brain sections were used as a source of native paired helical filament (PHF)-tau and Aβ rather than synthetic tau aggregates or Aβ fibrils generated in vitro to measure the affinity and selectivity of [(18)F]T807 to tau and Aβ. Brain uptake and biodistribution of [(18)F]T807 in mice were also tested.
Results: In vitro autoradiography results show that [(18)F]T807 exhibits strong binding to PHF-tau-positive human brain sections. A dissociation constant (Kd) of [(18)F]T807 (14.6 nM) was measured using brain sections from the frontal lobe of AD patients. A comparison of autoradiography and double immunohistochemical staining of PHF-tau and Aβ on adjacent sections demonstrated that [(18)F]T807 binding colocalized with immunoreactive PHF-tau pathology, but did not highlight Aβ plaques. In vivo studies in mice demonstrated that [(18)F]T807 was able to cross the blood-brain barrier and washed out quickly.
Conclusions: [(18)F]T807 demonstrates high affinity and selectivity to PHF-tau as well as favorable in vivo properties, making this a promising candidate as an imaging agent for AD.
Keywords: Alzheimer’s disease; Amyloid β; Autoradiography; Imaging; Tau; [(18)F]T807.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Similar articles
- Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, Higuchi M, Halldin C, Nordberg A. Lemoine L, et al. Alzheimers Res Ther. 2017 Dec 11;9(1):96. doi: 10.1186/s13195-017-0325-z. Alzheimers Res Ther. 2017. PMID: 29229003 Free PMC article. - Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y. Okamura N, et al. J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15. J Nucl Med. 2013. PMID: 23857514 - Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Chien DT, et al. J Alzheimers Dis. 2013;34(2):457-68. doi: 10.3233/JAD-122059. J Alzheimers Dis. 2013. PMID: 23234879 - [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H. Watanabe H. Yakugaku Zasshi. 2017;137(11):1361-1365. doi: 10.1248/yakushi.17-00156. Yakugaku Zasshi. 2017. PMID: 29093372 Review. Japanese. - Molecular imaging of dementia.
Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T. Mori T, et al. Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Psychogeriatrics. 2012. PMID: 22712644 Review.
Cited by
- Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age-related tauopathy and Alzheimer's disease.
Josephs KA, Tosakulwong N, Weigand SD, Graff-Radford J, Schwarz CG, Senjem ML, Machulda MM, Kantarci K, Knopman DS, Nguyen A, Reichard RR, Dickson DW, Petersen RC, Lowe VJ, Jack CR Jr, Whitwell JL. Josephs KA, et al. Sci Transl Med. 2024 Jul 24;16(757):eado8076. doi: 10.1126/scitranslmed.ado8076. Epub 2024 Jul 24. Sci Transl Med. 2024. PMID: 39047115 Free PMC article. - Medial amygdalar tau is associated with anxiety symptoms in preclinical Alzheimer's disease.
Li JS, Tun SM, Ficek-Tani B, Xu W, Wang S, Horien CL, Toyonaga T, Nuli SS, Zeiss CJ, Powers AR, Zhao Y, Mormino EC, Fredericks CA. Li JS, et al. bioRxiv [Preprint]. 2024 Jun 3:2024.06.03.597160. doi: 10.1101/2024.06.03.597160. bioRxiv. 2024. PMID: 38895308 Free PMC article. Updated. Preprint. - Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy.
Sheng L, Bhalla R. Sheng L, et al. Neurochem Res. 2024 Sep;49(9):2273-2302. doi: 10.1007/s11064-024-04178-w. Epub 2024 Jun 6. Neurochem Res. 2024. PMID: 38844706 Free PMC article. Review. - Distinct Heterocyclic Moieties Govern the Selectivity of Thiophene-Vinylene-Based Ligands Towards Aβ or Tau Pathology in Alzheime's Disease.
Björk L, Shirani H, Todarwal Y, Linares M, Vidal R, Ghetti B, Norman P, Klingstedt T, Nilsson KPR. Björk L, et al. European J Org Chem. 2023 Nov 2;26(41):e202300583. doi: 10.1002/ejoc.202300583. Epub 2023 Sep 11. European J Org Chem. 2023. PMID: 38585413 Free PMC article. - Mitochondrial disorders leading to Alzheimer's disease-perspectives of diagnosis and treatment.
Pszczołowska M, Walczak K, Miśków W, Mroziak M, Chojdak-Łukasiewicz J, Leszek J. Pszczołowska M, et al. Geroscience. 2024 Jun;46(3):2977-2988. doi: 10.1007/s11357-024-01118-y. Epub 2024 Mar 8. Geroscience. 2024. PMID: 38457008 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical